

## CERTIFICATE OF FINISHED PRODUCT ANALYSIS

<b>Product Name:</b>	<b>Clindacan 600 Injection (Clindamycin Phosphate Injection IP)</b>		
<b>Batch No.</b>	25AF102A	<b>A.R. No.</b>	PV250601
<b>Batch Size</b>	20050 Ampoules	<b>Sample Quantity</b>	60 Nos
<b>Mfg. Date</b>	06/2025	<b>Date of Testing</b>	22/06/2025
<b>Exp. Date</b>	05/2027	<b>Date of Release</b>	10/07/2025
<b>Reference Batch No</b>	25AF102	<b>MFG. Lic. No.</b>	N-MB-2023/263




Sr. No.	Test	Specification	Observation
1.	<b>Description</b>	An almost colorless solution	Clear and colorless solution
2.	<b>Identification</b> A. By TLC  B. By Assay	<p>The principal spot in the chromatogram obtained with the test solution corresponds to the principal spot in the chromatogram obtained with the reference solution.</p> <p>In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).</p>	Complies
3.	<b>pH</b>	Between 5.5 to 7.0	6.36
4.	<b>Related Substance</b>	Inject the reference solution. The test is not valid unless the resolution between the peaks due to lincomycin hydrochloride and clindamycin phosphate is not less than 7.7. Inject the test solution. The sum of the areas of all the secondary peaks is not more than 8.0 per cent, calculated by area normalization. Ignore any peak obtained due to benzyl alcohol.	Complies
5.	<b>Extractable Volume</b>	NLT 4.0 ml	4.0 ml

**CERTIFICATE OF FINISHED PRODUCT ANALYSIS**

<b>Product Name:</b>	<b>Clindacan 600 Injection (Clindamycin Phosphate Injection IP)</b>		
<b>Batch No.</b>	25AF102A	<b>A.R. No.</b>	PV250601
<b>Batch Size</b>	20050 Ampoules	<b>Sample Quantity</b>	60 Nos
<b>Mfg. Date</b>	06/2025	<b>Date of Testing</b>	22/06/2025
<b>Exp. Date</b>	05/2027	<b>Date of Release</b>	10/07/2025
<b>Reference Batch No</b>	25AF102	<b>MFG. Lic. No.</b>	N-MB-2023/263

<b>6.</b>	<b>Bacterial Endotoxins</b>	NMT 6.0 Endotoxin unit per mg of Clindamycin Phosphate	Less than 6.0 Endotoxin unit per mg of Clindamycin Phosphate
<b>7.</b>	<b>Particulate Matter</b>	Injections that are solutions, when examined under suitable conditions of visibility, are clear and practically free from particles that can be observed on visual inspection by the unaided eye.	Complies
<b>8.</b>	<b>Sterility</b>	Should be Sterile	Sterile
<b>9.</b>	<b>Assay:</b> Each ml contains: <b>Clindamycin Phosphate IP Eq. to anhydrous Clindamycin 150 mg</b>	135.0 mg to 180.0 mg (90.0 % to 120.0 %)	152.36 mg 101.57 %

**Remark:** The sample is complies as per IP /BP/ USP/IH specification.

	<b>Prepared By</b>	<b>Checked By</b>	<b>Approved By</b>
<b>Sign/Date</b>	 10/07/2025	 10/07/2025	 10/07/2025
<b>Name</b>	<b>Prayash</b>	<b>Manisha Thakur</b>	<b>Bhupinder Navet</b>
<b>Designation</b>	<b>Officer QC</b>	<b>Executive-QC</b>	<b>Head-QC</b>